A VACV expressing a soluble TGF-β inhibitor was able to eliminate head and neck squamous cell carcinoma (HNSCC) tumors that were resistant to treatment with a control VACV containing B2R and TK deletions. The gene discussed is TKT; the disease is head and neck squamous cell carcinoma.